Article: Isocarboxazid

6101-100px-isocarboxazid-isocarboxazid.png
Isocarboxazid
Systematic (IUPAC) name
N'-benzyl-5-methyl-oxazole-3-carbohydrazide
Identifiers
CAS number 59-63-2
ATC code N06AF01
PubChem 3759
DrugBank APRD00701
Chemical data
Formula C12H13N3O2
Mol. weight 231.26
Pharmacokinetic data
Bioavailability  ?
Metabolism Liver
Half life  ?
Excretion Urine
Therapeutic considerations
Pregnancy cat.

C (USA)

Legal status

â„ž Prescription only

Routes Oral

Isocarboxazid is a nonselective hydrazine-derived monoamine oxidase inhibitor used in treatment resistant depression.

Uses

Approved

In the United States, isocarboxazid is approved for the treatment of depression.

Off-Label/Unapproved/Investigational

A randomized controlled trial published in December of 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.[1]

Brand Names

United States

MARPLAN® by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough Marplan® to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product Marplan® (isocarboxazid) from Roche."[2]

The maximum daily dose of isocarboxazid is 60mg.

Resources